Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

BIOTRONIK Announces 12-Month Results from 4EVER Study

Published: Monday, November 19, 2012
Last Updated: Monday, November 19, 2012
Bookmark and Share
Results show strong evidence of benefits for lower limb intervention when using Pulsar stents.

BIOTRONIK has announced the twelve-month results from the prospective, multicenter, single-arm 4EVER study, which demonstrates the efficacy and safety of BIOTRONIK’s Pulsar self-expanding stent system in 120 superficial femoral artery (SFA) patients.

Twelve-month data for the full cohort showed an impressive 81.4% primary patency rate and a freedom from TLR (target lesion revascularization) rate of 89.3%.

The Pulsar-18 subgroup, which had an average lesion length of 10.5 cm, showed a primary patency rate of 73.4% and freedom from TLR rate of 85.2%.

Dr. Marc Bosiers, Chief of Surgery at AZ Sint-Blasius in Dendermonde, Belgium, initiated the study, which investigated both the acute and long-term performance of 4F-compatible devices.

The study examined the efficacy of Pulsar stents and the feasibility of treating patients with 4F devices from BIOTRONIK, including the Fortress 4F sheath, Passeo-18 balloon, and Astron Pulsar and Pulsar-18 stents.

“These results are certainly in line with published studies of similar lesion lengths using thick strut, high radial force stents,” said Dr. Koen Deloose, AZ Sint-Blasius in Dendermonde, Belgium.

Deloose continued, “We generally find that the vast majority of lesions can be treated with Pulsar stents. The fact that the 4EVER study showed 100% technical success in a population where 31% of lesions were calcified-with patency rates and freedom from TLR rates similar to high radial force stents-seems to support this. In fact, analysis of calcified vs. non-calcified lesions showed patency rates of 80.2% and 82.0% respectively with no statistical significant difference. In addition, no clinical data is available that proves whether any currently available self-expanding stent can successfully treat heavily calcified ‘coral reef’ lesions.”

Pulsar stents feature an innovative, highly flexible design coated with PROBIO, a silicon carbide layer that improves the stent's hemocompatibility and biocompatibility-which is believed to contribute to the stent’s excellent clinical results.

Pulsar-18 is available in diameters from 4–7 mm and lengths from 20–200 mm and deliverable through a 4F sheath. The recently launched Pulsar-35 stent uses the exact same stent technology for use on a 0.035"/6F delivery system.

“The 4EVER results strongly suggest that Pulsar stent systems with optimal radial force combined with high flexibility are superior to systems which concentrate mainly on high radial force in treating SFA disease,” explained Alain Aimonetti, Vice President Sales and Business Development, BIOTRONIK Vascular Intervention.

Aimonetti continued, “Our expectations are for an even greater differential in clinical outcomes when the 24-month data are presented. We have invested heavily in clinical studies aimed at providing data to further support Pulsar stents in a variety of clinical settings.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Approves First Single-Lead ICD with Atrial Sensing
BIOTRONIK’s Lumax DX system could help the 50,000 patients each year who may benefit from atrial sensing, without pacing indication.
Tuesday, September 17, 2013
BIOTRONIK Orsiro Hybrid DES Lives Up to Abbott’s XIENCE PRIME™
Positive 9 month results from BIOFLOW-II clinical trial and 12 month results from BIOFLOW-III registry presented at EuroPCR congress.
Tuesday, July 09, 2013
BIOTRONIK Home Monitoring® Reduces Inappropriate ICD Shocks by 52%
ECOST trial results published in European Heart Journal.
Friday, December 21, 2012
First CRT-D Patient Enrolled in the EuroEco ICD/CRT-D Trial
Study to assess the economic effects of BIOTRONIK Home Monitoring®.
Tuesday, July 24, 2012
Large-Scale BIOTRONIK SPIRIT-ICD Study Enrollment Complete
SPIRIT-ICD study explores benefits of intensified diagnostic follow-up and timely therapeutic intervention for high-risk patient group.
Monday, July 09, 2012
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos